Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.47 |
| ▸ | RARB | P10826 | 6/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CTSV | O60911 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | RARA | P10276 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8081767 | 0.95 | HSD11B1 (0.49) | HSD11B1RARBHSD17B10ALDH1A1HPGD | |
| SCHEMBL1368894 | 0.89 | LPL (0.37) | HSD11B1CA2HSD17B10ALDH1A1NISCH | |
| SCHEMBL5321366 | 0.85 | NPC1 (0.37) | HSD11B1RARBCA2CA1CTSV | |
| SCHEMBL1371196 | 0.82 | TP53 (0.44) | CTSVCTSLALDH1A1NISCHSMN1; SMN2 | |
| SCHEMBL7210744 | 0.80 | HSD11B1 (0.49) | HSD11B1RARBCTSVCTSLALDH1A1 | |
| SCHEMBL19410790 | 0.80 | SIGMAR1 (0.34) | HSD11B1LMNAHIF1A | |
| SCHEMBL27647893 | 0.79 | TDP1 (0.48) | MEN1KMT2A | |
| SCHEMBL27976761 | 0.78 | LTA4H (0.51) | HSD17B10ALDH1A1HPGDSMN1; SMN2NPC1 | |
| SCHEMBL7145876 | 0.78 | LPL (0.45) | HSD11B1 | |
| SCHEMBL2722607 | 0.77 | HSD11B1 (0.44) | HSD11B1RARBHSD17B10ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1423386-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | claimed |
| WO-2003022842-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-20 | — | — | WO | claimed |
| CN-110573013-B | Plant disease control agent | 明治制果药业株式会社 | 2021-10-29 | — | — | CN | disclosed |
| CN-109311844-B | Triazine compound, method for producing same, and organic electroluminescent element containing same as constituent component | 东曹株式会社 | 2021-07-20 | — | — | CN | disclosed |
| CN-110573013-A | Plant disease control agent | 明治制果药业株式会社 | 2019-12-13 | — | — | CN | disclosed |
| EP-2778160-B1 | CYCLIC AZINE COMPOUND HAVING NITROGEN-CONTAINING FUSED AROMATIC GROUP, METHOD FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME AS CONSTITUENT COMPONENT | TOSOH CORP (JP) | 2018-01-10 | — | — | EP | disclosed |
| US-9812652-B2 | Cyclic azine compound having adamantyl group, production method, and organic electroluminescent device containing it as constituent component | TOSOH CORPORATION (JP) | 2017-11-07 | — | — | US | disclosed |
| US-9624193-B2 | Cyclic azine derivatives, processes for producing these, and organic electroluminescent element containing these as component | TOSOH CORPORATION (JP) | 2017-04-18 | — | — | US | disclosed |
| US-20160372678-A1 | CYCLIC AZINE COMPOUND HAVING ADAMANTYL GROUP, PRODUCTION METHOD, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING IT AS CONSTITUENT COMPONENT | TOSOH CORPORATION (JP) | 2016-12-22 | — | — | US | disclosed |
| US-9252368-B2 | Cyclic azine compound having nitrogen-containing condensed aromatic group, method for producing same, and organic electroluminescent device comprising same as constituent component | TOSOH CORPORATION (JP) | 2016-02-02 | — | — | US | disclosed |
| US-20150329544-A1 | CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT | TOSOH CORPORATION (JP) | 2015-11-19 | — | — | US | disclosed |
| EP-2468731-A1 | CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT | Tosoh Corporation (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-20110288295-A1 | 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | SAGAMI CHEMICAL RESEARCH INSTITUTE (JP) | 2011-11-24 | — | — | US | disclosed |
| EP-2361909-A1 | 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME | Tosoh Corporation (JP) | 2011-08-31 | — | — | EP | disclosed |
| US-20110190494-A1 | 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME AS CONSTITUENT COMPONENT | TOSOH CORPORATION (JP) | 2011-08-04 | — | — | US | disclosed |
| EP-2351750-A1 | 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME AS CONSTITUENT COMPONENT | Tosoh Corporation (JP) | 2011-08-03 | — | — | EP | disclosed |
| EP-1423386-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003022842-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-20 | — | — | WO | disclosed |
| EP-1051394-A1 | POTASSIUM CHANNEL INHIBITORS | Icagen, Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999037607-A1 | POTASSIUM CHANNEL INHIBITORS | ICAGEN, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288295-A1 | 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | VDAC1, MT-ND5, TRPC5 | HSD11B1 2006/4885RARB 3639/4885CA2 1991/4885 |
| US-20160372678-A1 | CYCLIC AZINE COMPOUND HAVING ADAMANTYL GROUP, PRODUCTION METHOD, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING IT AS CONSTITUENT COMPONENT | CHRM1, AFF1, AZI2 | HSD11B1 1098/4885RARB 4620/4885CA2 2072/4885 |
| US-20110190494-A1 | 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME AS CONSTITUENT COMPONENT | ASH2L, SETDB1, KAT5 | HSD11B1 2447/4885RARB 3020/4885CA2 1417/4885 |
| US-20150329544-A1 | CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT | CPNE4, EPB41, AZI2 | HSD11B1 4406/4885RARB 2851/4885CA2 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.